Prostate cancer: a new combination approach using ARSI therapy with CD105 blocker to overcome resistance
Official title: A translational study of a synthetic lethality interaction of CD105 and androgen receptor signaling axis for castration-resistant prostate cancer patients
Funded at Cedars-Sinai Medical Center · NIH-11360657 · Data updated 2026-11-12
A new treatment concept aims to help men with advanced prostate cancer that stops responding to standard ARSI therapy by pairing ARSI treatment with a CD105 blocker to tackle resistance.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cedars-Sinai Medical Center NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2026 |
| Award (this year) | $1,813,962 |
| NIH project number | 4R01CA292654-03 |
| Project ID | NIH-11360657 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are men with castration-resistant prostate cancer who have progressed on standard ARSI therapy and could be eligible for future trials testing the combination approach.
✕Less likely to help
Patients whose tumors do not rely on the CD105 axis or who cannot tolerate antibody-based therapies may receive limited or no benefit.
What this research studies
This project explores how combining next-generation androgen receptor signaling inhibitors with a CD105 antagonist could overcome resistance driving prostate cancer progression. Researchers have found that ARSI treatment increases CD105, which then activates signals that help cancer cells survive; blocking CD105 may disrupt these survival pathways. The study uses preclinical models to understand how CD105, AR variants, FGFR3 signaling, and glutamine metabolism interact to sustain resistance, with the goal of translating these insights into a more effective treatment strategy. If successful, this work could lead to new clinical options for patients whose cancer no longer responds to current ARSI therapy.
Why it matters
Potential benefit: If successful, patients may experience renewed sensitivity to ARSI therapy and slower disease progression.
How similar studies have gone: Prior work showed feasibility of combining ARSI with CD105 blockade in a phase 2 trial, supporting further investigation.
Where this research is happening
-
Cedars-Sinai Medical Center
Los Angeles, United States Active
Researchers
- Principal investigator: Bhowmick, Neil a. — Cedars-Sinai Medical Center
- Study coordinator: Bhowmick, Neil a.
Related research
Other NIH-funded projects on the same topics.
-
Understanding how aggressive cell states emerge in castration-resistant prostate cancer
A research project aims to uncover the hidden cell states that help prostate cancer resist standard therapy and how these states arise early in tumor development.
-
Enhancer RNA CYP11A1-eRNA in castration-resistant prostate cancer
Researchers are testing a new RNA-based target, CYP11A1-eRNA, to see if blocking it can hamper the growth of castration-resistant prostate cancer in the lab and animal models.
-
Targeted Immunostimulatory Dual Drug Conjugates for Heterogeneous Metastatic Prostate Cancer
Researchers are testing a targeted therapy approach to help people with metastatic castration-resistant prostate cancer by boosting the immune system and delivering drugs directly to cancer cells.
-
Androgen Receptor Action in Prostate Cancer that Stops Responding to Therapy
This grant supports research to understand why certain prostate cancers stop responding to AR-targeted therapies and to find new ways to target them.
-
Hyperactive methylation in a hard-to-treat prostate cancer subtype
Researchers are studying a newly identified methylation-heavy group of advanced prostate cancer to understand its biology and find clues for better treatments.
-
Therapeutic Targeting of Lineage Plasticity in Advanced Prostate Cancer
A cancer research effort aimed at understanding and tackling how aggressive prostate cancers become resistant to standard AR-targeted therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.